1: (ROOT (S (S (NP (NN Collaboration) (S (VP (TO To) (VP (VB Develop) (NP (NP (NML (HYPH COVI-19) (NN -cell)) (NNP TherapyBaylor) (NNP College)) (PP (IN of) (NP (NNP Medicine)))))))) (VP (VBZ is) (VP (VBG teaming) (PRT (RP up)) (PP (IN with) (NP (NNP AlloVir))) (S (VP (TO to) (VP (VB work) (PP (IN on) (S (VP (VBG developing) (NP (NN -cell) (NNS therapies)) (PP (IN against) (NP (DT the) (NML (CD COVI-19)) (NN outbreak)))))))))))) (: ;) (S (NP (DT this) (NN collaboration)) (VP (MD will) (VP (VB build) (PP (IN on) (NP (VBG existing) (NN work))) (S (VP (TO to) (VP (VB develop) (NP (PP (IN off) (NP (DT the) (NN shelf))) (NP (NP (NN cell) (NNS therapies)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB identify) (CC and) (VB eliminate) (NP (JJ specific) (NNS viruses)))))))))))))) (. .)))
2: (ROOT (S (NP (NNP AlloVir)) (VP (VP (VBZ has) (VP (VBN been) (VP (VBG investigating) (SBAR (WHADVP (WRB how)) (S (VP (TO to) (VP (VB help) (S (NP (NP (DT those)) (PP (IN with) (NP (VBN weakened) (JJ immune) (NNS systems)))) (VP (VB cope) (PP (IN with) (NP (JJ viral) (NNS pathogens)))))))))))) (, ,) (CC and) (VP (VBP have) (VP (VBN accumulated) (NP (NP (NP (NN evidence)) (PP (IN of) (NP (NN improvement)))) (PP (IN in) (NP (NP (DT an) (NN approach)) (SBAR (WHNP (WDT that)) (S (VP (VBZ entails) (S (VP (VBG exposing) (NP (NN donor) (NNS -cells)) (PP (IN to) (NP (NP (NP (NNS cytokines)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN combined) (PP (IN with) (NP (JJ viral) (NNS fragments)))))))) (ADVP (RB thereby)) (VP (VBG equipping) (NP (DT the) (JJ immune) (NNS cells)) (S (VP (TO to) (VP (VB recognize) (CC and) (VB help) (S (VP (VB eliminate))) (NP (JJ certain) (NNS pathogens))))))))))))))))))) (. .)))
3: (ROOT (S (PP (IN With) (NP (NP (NP (DT the) (ADJP (RBS most) (JJ advanced)) (NN expression)) (PP (IN of) (NP (DT this) (NN approach)))) (VP (VBG being) (NP (NP (NML (NNP Viraly) (HYPH -) (NNP M) (NN -cell)) (NNP Therapy)) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (VP (VBN designed) (S (VP (TO to) (VP (VB kill) (NP (NP (CD 6) (NNS viruses)) (SBAR (WHNP (WDT that)) (S (ADVP (RB commonly)) (VP (VBP affect) (NP (JJ immunocompromised) (NNS patients))))))))))))))))) (: ;) (S (NP (DT the) (NN drug)) (VP (VBD was) (VP (VBN moved) (PP (IN into) (NP (NN phase) (CD 2))) (PP (IN in) (NP (CD 2014))) (PP (IN with) (NP (JJ enough) (NNS data) (S (VP (TO to) (VP (VB encourage) (NP (NP (NN planning)) (PP (IN of) (NP (DT a) (NML (JJ late) (NN phase)) (NN program)))))))))))) (. .)))
4: (ROOT (S (NP (DT This) (JJ same) (NN approach)) (VP (MD will) (VP (VB be) (VP (VBN applied) (PP (IN to) (NP (NML (NNP SAR) (HYPH -) (CD Co-2)) (JJ specific) (NNS -cells))) (PP (IN with) (NP (DT the) (NN goal) (S (VP (TO to) (VP (VB create) (NP (NP (DT an) (NML (PP (IN off) (NP (DT the) (NN shelf)))) (NN therapy)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG targeting) (NP (NP (ADJP (JJ specific) (CC and) (JJ similar)) (NNS viruses)) (PP (JJ such) (IN as) (NP (NP (NNP SAR) (HYPH -) (NNP CoV)) (, ,) (NP (NNP MER) (HYPH -) (NNP CoV)) (CONJP (RB as) (RB well) (IN as)) (NP (JJ endemic) (NNS coronaviruses))))))))))))))))))))) (. .)))
5: (ROOT (S (NP (DT The) (NN plan)) (VP (VBZ is) (S (VP (TO to) (VP (VP (VB position) (NP (JJ specific) (NNS -cells)) (PP (IN for) (NP (NP (NN use)) (PP (IN as) (NP (NN monotherapy)))))) (CC and) (VP (VB incorporate) (NP (DT the) (NN coronavirus)) (PP (IN into) (NP (NP (CD ALVR106)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (NP (NP (DT a) (JJ preclinical) (NN asset)) (VP (VBN geared) (PP (IN towards) (NP (NN community) (VBN acquired) (JJ respiratory) (NNS viruses))))))))))))))) (. .)))
6: (ROOT (S (S (VP (VBG Using) (NP (DT this) (NN approach)))) (NP (NNS researchers)) (VP (VBP hope) (S (VP (TO to) (VP (VB improve) (NP (DT the) (NNS outcomes)) (PP (IN for) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VP (VBP are) (ADJP (VBN immunocompromised))) (CC and) (VP (VBP become) (ADJP (VBN exposed) (PP (IN to) (NP (NP (NNP SAR) (HYPH -) (CD Co-2)) (CC and) (NP (NP (JJ other) (NNS viruses)) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (VB overwhelm) (NP (PRP$ their) (VBN weakened) (JJ immune) (NNS systems)))))))))))))))))))) (. .)))
7: (ROOT (S (S (NP (DT A) (NN timeline)) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN provided) (PP (IN for) (NP (DT this) (CD COVI-19) (NN program))))))) (, ,) (CC but) (S (NP (NP (DT the) (NN interest)) (PP (IN in) (NP (NP (NNS coronaviruses)) (ADJP (JJ other) (PP (IN than) (NP (NNP SAR) (HYPH -) (CD Co-2))))))) (VP (MD could) (VP (VB mean) (SBAR (IN that) (S (NP (JJ such) (NNS therapies)) (VP (MD may) (ADVP (RB still)) (VP (VB be) (ADJP (JJ relevant)) (SBAR (ADVP (RB even)) (IN if) (S (NP (PRP they)) (VP (VBP miss) (NP (NP (DT the) (NN window)) (IN of) (NP (NP (NN opportunity)) (PP (IN for) (NP (NP (DT these) (NNS treatments)) (PP (IN for) (NP (NP (DT the) (NN pathogen)) (PP (ADVP (RB currently)) (IN at) (NP (NN hand))))))))))))))))))) (. .)))
8: (ROOT (S (S (NP (NP (JJ Other) (NNS companies)) (SBAR (WHNP (WDT that)) (S (VP (VBP r) (HYPH -) (VBP purpose) (NP (VBG existing) (NNS drugs)))))) (VP (MD may) (VP (VB have) (NP (ADJP (RBR more) (JJ advanced)) (NNS assets))))) (, ,) (CC but) (S (NP (NP (PRP it))) (VP (VBZ is) (ADJP (JJ worth) (NP (VBG noting))) (SBAR (IN that) (S (NP (NN -cell) (NN therapy)) (VP (MD may) (VP (VB help) (S (VP (TO to) (VP (VB fill) (PRT (RP in)) (NP (NP (NNS gaps)) (PP (IN within) (NP (DT the) (NN treatment) (NN landscape))))))))))))) (. .)))
9: (ROOT (SINV ('' `) (S (PP (VBN Given) (NP (NP (DT the) (JJ worldwide) (NN coronavirus) (NN pandemic)) (CC and) (NP (NP (NNS risks)) (PP (IN to) (NP (NP (JJ immunocompromised) (NNS patients)) (UCP (ADVP (RB now)) (CC and) (PP (IN in) (NP (DT the) (NN future))))))))) (, ,) (NP (PRP we)) (VP (VBP believe) (SBAR (S (NP (NP (PRP it))) (VP (VBZ is) (NP (PRP$ our) (NN responsibility)) (S (VP (TO to) (VP (VP (VB leverage) (NP (PRP$ our) (JJ scientific) (NN expertise))) (CC and) (VP (VB allocate) (NP (NNS resources)) (PP (IN for) (NP (DT an) (JJ allogeneic) (, ,) (NML (PP (IN of) (HYPH -) (NP (JJ th) (HYPH -) (NN shelf)))) (, ,) (ADJP (NN coronaviru) (HYPH -) (JJ specific)) (NN -cell) (NN program)))))))))))) (, ,) ('' ') (VP (VBD said)) (NP (NP (NP (NNP Ann) (NNP Leen)) (, ,) (NP (NNP P) (. ..))) (, ,) (NP (NP (NNP AlloVir) (NML (NNP C) (HYPH -) (NNP Founder))) (, ,) (NP (NNP Chief) (NNP Scientific) (NNP Officer)) (, ,) (CC and) (NML (NP (NNP Professor)) (PP (IN of) (NP (NNP Pediatrics))) (PP (IN at) (NP (NP (NNP Baylor) (NNP College)) (PP (IN of) (NP (NNP Medicine)))))))) (. .)))
10: (ROOT (S (ADVP (RB Together) (PP (IN with) (NP (NP (NNP Baylor) (NNP College)) (PP (IN of) (NP (NNP Medicine)))))) (NP (PRP we)) (VP (VBP have) (ADVP (RB already)) (VP (VBN advanced) (NP (CD two) (ADJP (ADJP (RB highly) (JJ innovative)) (JJ allogeneic)) (, ,) (NML (PP (IN of) (HYPH -) (NP (JJ th) (HYPH -) (NN shelf)))) (, ,) (NML (NML (JJ mult) (HYPH -) (NN virus)) (JJ specific) (NN -cell)) (JJ investigational) (NNS immunotherapies)))) (. .)))
11: (ROOT (S (NP (PRP We)) (VP (VBP believe) (SBAR (S (NP (PRP we)) (VP (MD can) (VP (VB apply) (NP (DT this) (JJ same) (NN approach)) (S (VP (TO to) (VP (VB develop) (NP (NP (DT a) (NN cell) (NN therapy)) (SBAR (S (VP (TO to) (VP (VB treat) (CC and) (VB prevent) (NP (NP (NN coronavirus) (NNS infections) (CC and) (NNS diseases)) (PP (IN in) (NP (JJ immunocompromised) (NNS patients))))))))))))))))) (. .) ('' ')))
